Analyst Ratings for Blueprint Medicines
Portfolio Pulse from Benzinga Insights
Analysts have provided ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter, with 5 bullish, 1 somewhat bullish, 3 indifferent, and 1 somewhat bearish. The average price target is $69.0, implying an upside from the current price of $50.45. This average has increased by 13.73% from the previous average price target of $60.67.
August 21, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a mostly bullish outlook on Blueprint Medicines (BPMC) with an average price target of $69.0, indicating potential upside.
The majority of analysts have a bullish or somewhat bullish rating on BPMC, indicating a positive outlook. The average price target is significantly higher than the current price, suggesting potential upside. This could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100